In trastuzumab-resistant HER2+ BC, combinatorial targeting of both HER2 (with trastuzumab) and IL-6 receptor (with tocilizumab) synergistically interferes with the tumor progression and metastasis by eradicating both E- and M-bCSCs (36); whereas, in the TNBC scenario, no such approach is available so far. Here, ERBB2 is linked to breast cancer.